chartexchange

Thryv Therapeutics to Participate in the UBS Global Biopharma Conference in London

PR Newswire | Nov 12, 2026 11:00 AM EST

Advancing Precision SGK1 Inhibitors at the Intersection of Electrical and Structural Heart Disease SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Thryv Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic...

Read original article